A UK/Canada Collaboration on the genetics of long-term diabetes complications and their risk factors among people with type 1 diabetes

英国/加拿大就 1 型糖尿病患者长期糖尿病并发症的遗传学及其危险因素开展合作

基本信息

  • 批准号:
    MR/T032340/1
  • 负责人:
  • 金额:
    $ 43.16万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2020
  • 资助国家:
    英国
  • 起止时间:
    2020 至 无数据
  • 项目状态:
    已结题

项目摘要

Over 100,000 Canadians and 380,000 in the UK overall have type 1 diabetes. People with type 1 diabetes require lifelong insulin injections to replace insulin synthesized by specialized cells in their pancreas that have died due to an immune process. Currently there are few treatments to prevent or delay the underlying destruction of insulin producing cells. However recent studies have shown that many people with type 1 diabetes do in fact still produce small amounts of insulin. This is important because these people have less severe diabetes: they require lower doses of insulin; have better control of their blood sugar levels; are at lower risk for the development of low blood sugar; and also importantly at lower risk for long-term complications of diabetes, including eye, kidney and heart diseases which are major health problems. However, we have little understanding of the factors that result in differences in insulin production capacity between people with type 1 diabetes. Genetics provides a unique opportunity to identify causal factors for important biomedical measures, such as varying insulin production in people with type 1 diabetes. We already conducted a pilot study where we identified genetic variations different locations in the genome that are related to insulin production and have shown that residual insulin production is very strongly genetically determined. However we showed that only a small percentage of the genetic contribution is from known genes so that there are important genes still to discover. Furthermore we showed that age at onset of diabetes is one determinant of residual insulin production but that the genes determining age at onset only capture a small percentage of the genetic determination of residual insulin production. In this project we will use data and samples from ten different studies, with a total of ~12,200 people with type 1 diabetes, to allow us to identify the genetic factors that influence residual insulin production, age at onset and also glycaemic control separating those genes that influence these traits together from those that have specific effects on each trait. It is important to bring the collaboration together in order to maximise the size of the study to make it as powerful as possible and also to ensure standardised approach as that also increases the power for discovery. This would be the largest and most comprehensive study of this topic to date.Identifying the genetic factors is the first step to understanding the mechanisms, which could ultimately be used to develop new approaches to help preserve insulin production in people with type 1 diabetes. The work will also lead to ways to identify which people with diabetes are most appropriate participants for which clinical trials which will accelerate drug development programmes. Since insulin production is also abnormal in many people with type 2 diabetes, which affects over 2 million Canadians and over 4 million in the UK overall, the discoveries about pancreatic cell function that we will make will also lead to important insights and accelerate development of new treatments for some people with type 2 diabetes.
超过10万加拿大人和38万英国人患有1型糖尿病。1型糖尿病患者需要终身注射胰岛素,以取代胰腺中因免疫过程而死亡的专门细胞合成的胰岛素。目前,几乎没有治疗方法可以预防或延迟胰岛素产生细胞的潜在破坏。然而,最近的研究表明,许多1型糖尿病患者实际上仍然产生少量胰岛素。这一点很重要,因为这些人的糖尿病不太严重:他们需要较低剂量的胰岛素;更好地控制血糖水平;发生低血糖的风险较低;而且重要的是,糖尿病长期并发症的风险较低,包括眼睛,肾脏和心脏疾病,这些都是主要的健康问题。然而,我们对导致1型糖尿病患者之间胰岛素产生能力差异的因素知之甚少。遗传学提供了一个独特的机会,以确定重要的生物医学措施的因果因素,如1型糖尿病患者的胰岛素产生变化。我们已经进行了一项初步研究,在该研究中,我们确定了基因组中与胰岛素产生相关的不同位置的遗传变异,并表明残余胰岛素的产生是非常强烈的遗传决定的。然而,我们发现只有一小部分遗传贡献来自已知基因,因此仍有重要的基因有待发现。此外,我们发现糖尿病发病年龄是残余胰岛素产生的一个决定因素,但决定发病年龄的基因只占残余胰岛素产生遗传决定的一小部分。在这个项目中,我们将使用来自10项不同研究的数据和样本,共有约12,200名1型糖尿病患者,使我们能够确定影响残余胰岛素产生,发病年龄以及血糖控制的遗传因素,将影响这些特征的基因与对每个特征具有特定影响的基因分开。重要的是将合作结合在一起,以最大限度地扩大研究规模,使其尽可能强大,并确保标准化的方法,因为这也增加了发现的力量。这将是迄今为止该主题最大和最全面的研究。确定遗传因素是理解机制的第一步,最终可以用于开发新方法,以帮助1型糖尿病患者保持胰岛素分泌。这项工作还将导致确定哪些糖尿病患者最适合参与哪些临床试验的方法,这将加速药物开发计划。由于胰岛素的产生在许多2型糖尿病患者中也是异常的,这影响了200多万加拿大人和400多万英国人,我们将对胰腺细胞功能的发现也将导致重要的见解,并加速一些2型糖尿病患者的新治疗方法的开发。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genetics of serum C-peptide in type 1 diabetes
1型糖尿病血清C肽遗传学
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    8.2
  • 作者:
    Paterson A. D.
  • 通讯作者:
    Paterson A. D.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Helen Colhoun其他文献

EFFECT OF THE GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE SELECT TRIAL
SELECT 试验中 GLP-1 受体激动剂司美格鲁肽对患有心血管疾病、超重或肥胖但无糖尿病患者的总心血管事件的影响
  • DOI:
    10.1016/s0735-1097(25)00862-9
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    22.300
  • 作者:
    Abraham Michael Lincoff;Helen Colhoun;Scott Emerson;G Kees Hovingh;Giray Kabakci;Steven Kahn;Ildiko Lingvay;Ana Laura De Souza Almeida Matos;CRISTOBAL MORALES;Soeren Rasmussen;Jose Francisco Kerr Saraiva;Benjamin M. Scirica;Francisco José Tinahones;Philippe van De Borne;Subodh Verma;Peter Ejvin Kure Weeke;Donna Ryan;John E. Deanfield
  • 通讯作者:
    John E. Deanfield
EPICARDIAL ADIPOSE TISSUE IS RELATED TO ARTERIAL STIFFNESS IN PATIENTS WITH CARDIO-METABOLIC DISEASE
  • DOI:
    10.1016/s0735-1097(16)31833-2
  • 发表时间:
    2016-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Shaween Al-Talabany;Faisel Khan;Graeme Houston;Helen Colhoun;Jonathan Weir-McCall;Daniel Leven;Fiona Dove;Deirdre Cassidy;Helen Looker;Chim Lang
  • 通讯作者:
    Chim Lang
LBP-032 Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis-a subgroup analysis from the SELECT trial
  • DOI:
    10.1016/s0168-8278(24)00599-3
  • 发表时间:
    2024-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sebastian Meyhöfer;Bertrand Cariou;Cintia Cercato;Helen Colhoun;Anne Duun-Henriksen;Iris Kliers;A. Michael Lincoff;Ildiko Lingvay;Michelle Long;Philip N. Newsome;Stephen Nicholls;Maria De Los Angeles Quiroga Pelaez;Ferruccio Santini;Arun J. Sanyal;Steven Kahn
  • 通讯作者:
    Steven Kahn
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study
晚期慢性肾脏病患者停用与继续使用二甲双胍的比较:一项苏格兰全国范围的目标试验模拟研究
  • DOI:
    10.1053/j.ajkd.2024.08.012
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    8.200
  • 作者:
    Emilie J. Lambourg;Edouard L. Fu;Stuart McGurnaghan;Bryan R. Conway;Neeraj Dhaun;Christopher H. Grant;Ewan R. Pearson;Patrick B. Mark;John Petrie;Helen Colhoun;Samira Bell;Rory McCrimmon;Catherine Armstrong;Alistair Emslie-Smith;Robert Lindsay;Sandra MacRury;John McKnight;Donald Pearson;Brian McKinstry
  • 通讯作者:
    Brian McKinstry
Alirocumab Versus Ezetimibe Over 104 Weeks In Individuals With Hypercholesterolemia And High Cardiovascular Risk: Final Results From ODYSSEY COMBO II
  • DOI:
    10.1016/j.jacl.2016.03.095
  • 发表时间:
    2016-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mahfouz El Shahawy;Christopher Cannon;Dirk Blom;James McKenney;Bertrand Cariou;Guillaume Lecorps;Robert Pordy;Umesh Chaudhari;Helen Colhoun
  • 通讯作者:
    Helen Colhoun

Helen Colhoun的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Establishment of new UK/Canada Collaboration towards the Advancement of Magnetic Particle Imaging (MPI)
英国/加拿大建立新的合作关系以推动磁粒子成像 (MPI) 的发展
  • 批准号:
    MR/Y033795/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Research Grant
Biodiversity and forest entropy - a Canada, Germany and Sweden collaboration
生物多样性和森林熵——加拿大、德国和瑞典的合作
  • 批准号:
    575747-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Alliance Grants
Combating misinformation, fear and stigma in response to the Covid-19 outbreak: An international collaboration between Canada and Singapore
针对 Covid-19 疫情,打击错误信息、恐惧和污名:加拿大和新加坡之间的国际合作
  • 批准号:
    422650
  • 财政年份:
    2020
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Operating Grants
A UK/Canada Collaboration on the genetics of long-term diabetes complications and their risk factors among people with type 1 diabetes
英国/加拿大就 1 型糖尿病患者长期糖尿病并发症的遗传学及其危险因素开展合作
  • 批准号:
    409967
  • 财政年份:
    2019
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Operating Grants
Evidence-informed International Comparison of Prevention of Preterm Birth and Its Preventable Complications: a Japan-Canada Collaboration
预防早产及其可预防并发症的循证国际比较:日本与加拿大的合作
  • 批准号:
    404401
  • 财政年份:
    2019
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Miscellaneous Programs
Concordia Researchers visit to Mitsubishi Canada for collaboration
康考迪亚研究人员访问加拿大三菱公司进行合作
  • 批准号:
    515977-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Connect Grants Level 1
Establishing a Canada-France research collaboration to reduce drug- and sexual-related harms among HIV-positive and -negative MSM
建立加拿大-法国研究合作,以减少艾滋病毒阳性和阴性男男性行为者中与毒品和性有关的伤害
  • 批准号:
    365613
  • 财政年份:
    2017
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Miscellaneous Programs
From Surviving to Flourishing: A Patient-Oriented Research Collaboration Exploring Conditions of Successful Peer-Support Initiatives in Canada
从生存到繁荣:以患者为导向的研究合作,探索加拿大成功同伴支持计划的条件
  • 批准号:
    363913
  • 财政年份:
    2016
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Operating Grants
How do organizational factors influence interprofessional collaboration in primary healthcare settings in Quebec, Canada?
组织因素如何影响加拿大魁北克初级卫生保健机构中的跨专业合作?
  • 批准号:
    331885
  • 财政年份:
    2015
  • 资助金额:
    $ 43.16万
  • 项目类别:
Exploration of potential collaboration with Nautilus Biosciences Canada Inc.
探索与 Nautilus Biosciences Canada Inc. 的潜在合作
  • 批准号:
    470765-2014
  • 财政年份:
    2014
  • 资助金额:
    $ 43.16万
  • 项目类别:
    Interaction Grants Program
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了